Kkelsen RB, Valerie K, Amir C, Dent P, Schmidt-Ullrich RK: Dominant adverse EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene 1999, 18:4756?766. 20. Baselga J, Mendelsohn J, Kim YM, Pandiella A: Autocrine regulation of membrane transforming development factor-alpha cleavage. J Biol Chem 1996, 271:3279?284. 21. Levenson AS, Tonetti DA, Jordan VC: The oestrogen-like impact of 4-hydroxytamoxifen on induction of transforming development element alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. Br J Cancer 1998, 77:1812?819. 22. Pages G, Milanini J, Richard DE, Berra E, Gothie E, Vinals F, Pouyssegur J: Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann N Y Acad Sci 2000, 902:187?00. 23. Li Y, Bi Z, Yan B, Wan Y: UVB radiation induces expression of HIF-1alpha and VEGF by means of the EGFR/PI3K/DEC1 pathway. Int J Mol Med 2006, 18:713?19. 24. Di Girolamo N, Coroneo M, Wakefield D: Epidermal growth element receptor signaling is partially accountable for the elevated matrix metalloproteinase-1 expression in ocular epithelial cells soon after UVB radiation. Am J Pathol 2005, 167:489?03. 25. Jung SK, Lee KW, Kim HY, Oh MH, Byun S, Lim SH, Heo YS, Kang NJ, Bode AM, Dong Z, Lee HJ: Myricetin suppresses UVB-induced wrinkle formation and MMP-9 expression by inhibiting Raf. Biochem Pharmacol 2010, 79:1455?461. 26. Bucci B, D’Agnano I, Botti C, Mottolese M, Carico E, Zupi G, Vecchione A: EGF-R expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Res 1997, 17:769?74. 27. LeMaistre CF, Meneghetti C, Howes L, Osborne CK: Targeting the EGF receptor in breast cancer remedy. Breast Cancer Res Treat 1994, 32:97?03.tert-Butyl (2-iodoethyl)carbamate Price 28.933708-92-0 Chemical name Toi M, Hoshina S, Takayanagi T, Tominaga T: Association of vascular endothelial growth issue expression with tumor angiogenesis and with early relapse in major breast cancer.PMID:35954127 Gan 1994, 85:1045?049. 29. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, et al: ZD6474 inhibits vascular endothelial development issue signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62:4645?655. 30. Ciardiello F, Caputo R, Damiano V, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G: Antitumor effects of ZD6474, a little molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with more activity against epidermal development issue receptor tyrosine kinase. Clin Cancer Res 2003, 9:1546?556. 31. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M: ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther 2010, 9:592?03.32. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K: Modest in-frame deletion in the epidermal development issue receptor as a target for ZD6474. Cancer Res 2004, 64:9101?104. 33. Rustogi A, Budrukkar A, Dinshaw K, Jalali R: Management of locally sophisticated breast cancer: evolution and present practice. J Cancer Res T 2005, 1:21?0. 34. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG: High tumor levels of vascular endothelial development aspect predict poor response to systemic therapy in sophisticated breast cancer. Cancer res 2001, 61:5407?414. 35. Neskovic-Konstantinovi.
